Needham analyst Ami Fadia reiterates Seagen (NASDAQ:SGEN) with a Buy and maintains $160 price target.
Oppenheimer Upgrades Aurinia Pharmaceuticals to Outperform, Lowers Price Target to $31
Oppenheimer analyst Justin Kim upgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Perform to Outperform and lowers the price target from $33 to $31.